Historical Valuation
Sanara Medtech Inc (SMTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.78 is considered Undervalued compared with the five-year average of -9.97. The fair price of Sanara Medtech Inc (SMTI) is between 270.12 to 323.51 according to relative valuation methord. Compared to the current price of 24.65 USD , Sanara Medtech Inc is Undervalued By 90.87%.
Relative Value
Fair Zone
270.12-323.51
Current Price：24.65
90.87%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sanara Medtech Inc (SMTI) has a current Price-to-Book (P/B) ratio of 33.55. Compared to its 3-year average P/B ratio of 9.96 , the current P/B ratio is approximately 237.00% higher. Relative to its 5-year average P/B ratio of 9.88, the current P/B ratio is about 239.68% higher. Sanara Medtech Inc (SMTI) has a Forward Free Cash Flow (FCF) yield of approximately -0.41%. Compared to its 3-year average FCF yield of -1.01%, the current FCF yield is approximately -59.73% lower. Relative to its 5-year average FCF yield of -1.50% , the current FCF yield is about -72.85% lower.
P/B
Median3y
9.96
Median5y
9.88
FCF Yield
Median3y
-1.01
Median5y
-1.50
Competitors Valuation Multiple
AI Analysis for SMTI
The average P/S ratio for SMTI competitors is 77.38, providing a benchmark for relative valuation. Sanara Medtech Inc Corp (SMTI.O) exhibits a P/S ratio of 1.78, which is -97.69% above the industry average. Given its robust revenue growth of 21.51%, this premium appears sustainable.
Performance Decomposition
AI Analysis for SMTI
1Y
3Y
5Y
Market capitalization of SMTI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SMTI in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SMTI currently overvalued or undervalued?
Sanara Medtech Inc (SMTI) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.78 is considered Undervalued compared with the five-year average of -9.97. The fair price of Sanara Medtech Inc (SMTI) is between 270.12 to 323.51 according to relative valuation methord. Compared to the current price of 24.65 USD , Sanara Medtech Inc is Undervalued By 90.87% .
What is Sanara Medtech Inc (SMTI) fair value?
SMTI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sanara Medtech Inc (SMTI) is between 270.12 to 323.51 according to relative valuation methord.
How does SMTI's valuation metrics compare to the industry average?
The average P/S ratio for SMTI's competitors is 77.38, providing a benchmark for relative valuation. Sanara Medtech Inc Corp (SMTI) exhibits a P/S ratio of 1.78, which is -97.69% above the industry average. Given its robust revenue growth of 21.51%, this premium appears sustainable.
What is the current P/B ratio for Sanara Medtech Inc (SMTI) as of Jan 09 2026?
As of Jan 09 2026, Sanara Medtech Inc (SMTI) has a P/B ratio of 33.55. This indicates that the market values SMTI at 33.55 times its book value.
What is the current FCF Yield for Sanara Medtech Inc (SMTI) as of Jan 09 2026?
As of Jan 09 2026, Sanara Medtech Inc (SMTI) has a FCF Yield of -0.41%. This means that for every dollar of Sanara Medtech Inc’s market capitalization, the company generates -0.41 cents in free cash flow.
What is the current Forward P/E ratio for Sanara Medtech Inc (SMTI) as of Jan 09 2026?
As of Jan 09 2026, Sanara Medtech Inc (SMTI) has a Forward P/E ratio of 19.91. This means the market is willing to pay $19.91 for every dollar of Sanara Medtech Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sanara Medtech Inc (SMTI) as of Jan 09 2026?
As of Jan 09 2026, Sanara Medtech Inc (SMTI) has a Forward P/S ratio of 1.78. This means the market is valuing SMTI at $1.78 for every dollar of expected revenue over the next 12 months.